Shares of Flex Pharma Inc. (NASDAQ:FLKS) have earned an average rating of “Buy” from the seven research firms that are presently covering the company. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $19.96.

A number of equities analysts have commented on FLKS shares. Cantor Fitzgerald cut shares of Flex Pharma from a “buy” rating to a “hold” rating and cut their price target for the stock from $22.00 to $10.00 in a research note on Friday, October 14th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Flex Pharma in a research note on Saturday, October 15th. Zacks Investment Research raised shares of Flex Pharma from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a research note on Tuesday, November 1st. Piper Jaffray Cos. set a $15.00 price objective on shares of Flex Pharma and gave the company a “buy” rating in a research note on Wednesday, November 2nd. Finally, JMP Securities reaffirmed a “buy” rating on shares of Flex Pharma in a research note on Thursday, November 3rd.

In other news, insider Christoph H. Westphal purchased 8,870 shares of the stock in a transaction that occurred on Monday, November 7th. The stock was bought at an average cost of $5.70 per share, for a total transaction of $50,559.00. Following the acquisition, the insider now directly owns 3,934,118 shares of the company’s stock, valued at approximately $22,424,472.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christoph H. Westphal purchased 7,000 shares of the stock in a transaction that occurred on Tuesday, November 8th. The shares were purchased at an average price of $7.31 per share, with a total value of $51,170.00. Following the completion of the acquisition, the insider now directly owns 3,941,118 shares in the company, valued at $28,809,572.58. The disclosure for this purchase can be found here. Corporate insiders own 43.35% of the company’s stock.

Large investors have recently bought and sold shares of the stock. California State Teachers Retirement System raised its stake in Flex Pharma by 0.9% in the third quarter. California State Teachers Retirement System now owns 22,525 shares of the biotechnology company’s stock worth $265,000 after buying an additional 200 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Flex Pharma by 6.1% in the third quarter. BlackRock Fund Advisors now owns 532,931 shares of the biotechnology company’s stock valued at $6,278,000 after buying an additional 30,689 shares during the period. JPMorgan Chase & Co. raised its position in shares of Flex Pharma by 2.1% in the third quarter. JPMorgan Chase & Co. now owns 54,632 shares of the biotechnology company’s stock valued at $644,000 after buying an additional 1,100 shares during the period. CAM Group Holding A S raised its position in shares of Flex Pharma by 50.0% in the third quarter. CAM Group Holding A S now owns 225,000 shares of the biotechnology company’s stock valued at $2,650,000 after buying an additional 75,000 shares during the period. Finally, Highbridge Capital Management LLC bought a new position in shares of Flex Pharma during the second quarter valued at approximately $116,000. Institutional investors own 33.68% of the company’s stock.

Flex Pharma (NASDAQ:FLKS) opened at 7.00 on Friday. The company’s market cap is $115.71 million. Flex Pharma has a 1-year low of $4.55 and a 1-year high of $13.97. The stock’s 50 day moving average is $8.15 and its 200 day moving average is $10.52.

Flex Pharma (NASDAQ:FLKS) last released its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.07. Equities analysts anticipate that Flex Pharma will post ($2.54) earnings per share for the current fiscal year.

Flex Pharma Company Profile

Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.

5 Day Chart for NASDAQ:FLKS

Receive News & Stock Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related stocks with our FREE daily email newsletter.